ClinicalTrials.gg
RecruitingNCT06051890Updated Aug 7, 2026

Assessing Optimal XRB Initiation Points in Jail

A Phase 4 interventional study of Extended-Release Buprenorphine (XRB) and Sublingual Buprenorphine (SLB) in Opioid Use Disorder, sponsored by NYU Langone Health. Recruiting at 4 sites in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by NYU Langone Health · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing sublocade in Opioid-Related Disorders — 2 open to participants now, 2 under way, none of them phase 3. Sublocade · Opioid-Related Disorders.

Planned enrollment
3rd of 12
50 · median 21
Started
2025
with 1 other
Phase 4
5 of 12
2 open now
Registered
10th of 12
by date
Lead sponsor
2 of 12
NYU Langone Health

Among the 12 studies testing sublocade in Opioid-Related Disorders, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 10th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

2 of the 12 studies testing sublocade in Opioid-Related Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About sublocade

Sublocade: first FDA approval 2017 (SUBLOCADE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing sublocade in Opioid-Related Disorders, or all of them as a file.
02

Study summary

This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Corrections (MCHOC) as pre-trial detainees will be randomized at admission on a 1:1 basis to be inducted onto extended-release buprenorphine (XRB) at the time of admission (experimental condition) or remain in SLB (E-TAU; all participants will also receive naloxone). The two approaches will be compared with regard to (1) the percentage of participants released from jail with at least 7 days of buprenorphine in their system, (2) percentage of participants continuing MOUD treatment in the community, and (3) infractions related to buprenorphine diversion.

03

Conditions studied

  • Opioid Use Disorder
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Incarcerated men able to provide written in English.*
  • Unsentenced.
  • Entering the facility with a prescription for SLB and receiving SLB for at least the previous 3 days.
  • Minimum anticipated jail stay is 4 days.
  • Willing to accept being randomized to the experimental condition (i.e., transitioning to XRB while incarcerated).

Exclusion criteria

Exclusion Criteria:

  • Sentenced.
  • Allergy, or medical to either medication.
  • Chronic pain requiring opioid pain management or other contraindicated medications.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Transition to Extended-Release Buprenorphine (XRB)

    Participants randomized to transition to treatment with XRB.

    Drug: Extended-Release Buprenorphine (XRB)

  • Active comparator
    Sublingual Buprenorphine (SLB) Maintenance

    Participants randomized to remain on-treatment with SLB.

    Drug: Sublingual Buprenorphine (SLB)

Interventions

  • DrugSublocadeStudies of SublocadeSublocade pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    XRB (Sublocade) will be delivered as a pre-filled 2cc subcutaneous monthly injection, using a 300mg starting dose in most cases (100mg starting doses are available per the study team's clinical judgement). XRB consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades. Prior to an initial injection, the participant must be stable for several days or longer on sublingual buprenorphine (SLB) at doses of 8mg/day or higher. Participants will receive at least one XRB monthly injection prior to release, which investigators anticipate to usually be the 300mg dose. Some participants will be recruited earlier during the incarceration (or experience delayed release dates and then longer than anticipated incarcerations); XRB will be continued monthly from the time of induction to the day of release.

    Also known as: Sublocade

  • DrugBuprenorphineStudies of BuprenorphineBuprenorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Maintenance of existing SLB prescription (treatment as usual).

06

What researchers measure

Primary outcomes

  1. Percentage of participants released from jail with at least 7 days of buprenorphine in their system

    The percentage of participants leaving jail with at least 7 days of buprenorphine protection in their system. Measured using clinical and jail records.

    Time frame: Up to Month 6

Secondary outcomes

  1. Percentage of participants continuing MOUD treatment in the community

    Percentage of participants who continue to access medication for opioid use disorder (MOUD) once released from jail. This will be based on community clinic records indicating admission and retention.

    Time frame: Up to Month 9

07

Study locations

4 of 4 sites recruiting
  • Tufts University Health Sciences
    Boston, Massachusetts 02111, United States
    Recruiting
    • Thomas Stopka, Ph.D. · Principal investigator
  • Baystate Health
    Springfield, Massachusetts 01199, United States
    Recruiting
    • Peter Friedmann, MD · Principal investigator
  • Middlesex County House of Corrections
    New Brunswick, New Jersey 08902, United States
    Recruiting
    • · Contact732-297-3636
    • Kashif Siddiqi · Principal investigator
  • NYU Langone Health - 180 Madison Ave
    New York, New York 10016, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All of the de-identified individual participant data collected during the trial will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: david.farabee@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to david.farabee@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 48 non-industry phase 4 interventional studies under Opioid-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's planned 17 months is below that.

Counting every sponsor, half of 52 studies reached it within 32 months; a quarter within 20 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2023
First posted
Sep 25, 2023
StartActual
Jun 2, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Mar 1, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06051890
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Sep 25, 2023
Start date
Jun 2, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

David Farabee
Contact
David.farabee@nyulagone.org
310-963-0009
David Farabee, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sublocade

Start the discussion